



August 13, 2020
David Gang, MD, FCAP
Chair, Federal and State Affairs Committee
College of American Pathologists
1001 G Street NW, Suite 425W
Washington, DC 20001

Mr. Gang:

Thank you for your correspondence regarding the pricing of COVID-19 testing. The Pennsylvania Insurance Department (Department) appreciates the ongoing work of the College of American Pathologists in the national effort to combat the spread of COVID-19.

The Department's primary role is to protect Pennsylvania's consumers. In the current context of the global pandemic and ongoing response efforts, protection from unreasonable billing is critically important. While the Department recognizes that there will be some price variability in the current market for COVID-19 tests, the Department nevertheless expects that unjustifiably high prices will be reported to the appropriate authorities. The Department's Notice 2020-19 informed the Department's regulated community that unjustifiably high prices for COVID-19 tests have been reported; in light of this information, the Department encouraged its regulated community to be vigilant for any anomalous billing that insurers may encounter and to take action as warranted. We expect that policyholders will not be billed for physician-directed diagnostic tests and we appropriately urged the regulated community to report any potential billing abuses.

The Department appreciates your engagement with this issue as we continue to protect Pennsylvanians from unjustifiable billing practices at a time of heightened vulnerability.

Sincerely,

Megan Barbour
Policy Director, Pennsylvania Insurance Department
megbarbour@pa.gov